Cyblex MV 40.2 Tablet
By Cyblex MV
Rx
15 Tablet in a Strip

Composition
Voglibose(0.2mg) + Metformin(500mg) + Gliclazide(40mg)

Manufacturer - Eris Lifesciences Ltd
8th Floor, Commerce House IV, Prahladnagar, Ahmedabad – 380015 Gujarat, India

Expires on or after
July, 2027

liver
When it comes to the safety of your liver, it is important to be cautious while using Cyblex MV 40.2 Tablet. Patients with liver disease should take this medication with care, as it may require a dose adjustment. It is advisable to consult your doctor before starting Cyblex MV 40.2 Tablet. Typically, in individuals with mild to moderate liver disease, the medication is initially prescribed in a low dose. However, for patients with severe liver disease, the use of Cyblex MV 40.2 Tablet is not recommended. Take special care and always seek guidance from your healthcare provider to ensure the safe and appropriate use of this medication.

kidney
Cyblex MV 40.2 Tablet requires caution in kidney disease. Dosage adjustment and doctor consultation may be necessary. Not advised for severe kidney disease. Monitor kidney function regularly during use.

alcohol
It is not safe to drink alcohol while taking Cyblex MV 40.2 Tablet. It is advised to avoid alcohol consumption for safety.

driving
When your blood sugar is too low or high, it can affect your driving ability. It's best not to drive if you experience any of these symptoms.

pregnancy
Cyblex MV 40.2 Tablet is considered unsafe during pregnancy, as animal studies suggest potential harm to the fetus. Consult your doctor to discuss any risks and benefits associated with its use during pregnancy.

breastfeeding
Caution should be taken when using Cyblex MV 40.2 Tablet while breastfeeding. It is recommended to wait until the mother's treatment is finished and the drug is no longer in her system.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | ANTI DIABETIC |
Action Class | - |
₹248.56
Inclusive of all taxes
Content verified by

Dr. Archana Prabhakar
MBBS, M.Med (Family Medicine)
Last update on 01-Oct-2024